Johnson & Johnson’s recent insider trading activity, as reflected in SEC Form 4 filings, shows a pronounced selling bias, particularly in shares of CVRx Inc. (CVRX). Over the past year, the company executed 24 trades, with total sales amounting to $733,144.08 compared to just $98,812.77 in purchases. The most significant transactions occurred in November 2025, including a $534,309.72 sale on November 6, followed by additional disposals totaling $100,692.11 between November 7 and November 26. Earlier in February 2024, Johnson & Johnson also offloaded $96,142.25 worth of CVRX shares. The bulk of the buying activity, though minimal, consisted of small acquisitions—mostly under $1,000—through market purchases ("M" codes) on February 29, 2024.
The pattern suggests a steady divestment from CVRX, with no recent buys recorded. The absence of purchases in the latter half of 2025, coupled with concentrated selling, indicates a shift away from the position. While the earlier 2024 transactions included minor market buys, they were dwarfed by the scale of the sales. The data does not reflect trading in Johnson & Johnson’s own stock (JNJ) but rather its activity in CVRX, a medical device company. The filings show no trades involving other equities, reinforcing CVRX as the sole focus of recent insider transactions. The dollar-weighted trend leans decisively toward liquidation, with no counterbalancing accumulation.
AI-assisted summary